Healthcare Industry News: Poniard Pharmaceuticals
News Release - October 14, 2013
Gregory L. Weaver Joins Atossa Genetics' Board of DirectorsSEATTLE, WA--(Healthcare Sales & Marketing Network) - Atossa Genetics Inc. (NASDAQ: ATOS), The Breast Health Company™, announced today that Gregory L. Weaver has joined the Company's Board of Directors and has been appointed a member of the Audit Committee.
"Greg brings a wealth of financial and operational experience in the Life Sciences industry to Atossa's Board of Directors and Audit Committee, including mergers and acquisitions, licensing transactions, regulatory approvals, and new product launches, as well as strategic planning and cost control efforts," said Steven C. Quay, Chairman, President & CEO. "Greg's experience will be invaluable to the Board and to management as we continue to build the Company."
Weaver has built a successful career in executive financial and operations management serving as CFO of small to mid-cap public and private biotechnology companies. He currently serves as Chief Financial Officer, Senior Vice President, Treasurer and Corporate Secretary of Fibrocell Science, Inc. Prior to joining Fibrocell Science in September 2013, he served as CFO with the following public companies: Celsion Corp., Poniard Pharmaceuticals, Sirna Therapeutics (acquired by Merck), Nastech Pharmaceuticals, and ILEX Oncology (acquired by Genzyme), and venture funded firms Talyst, Inc. and Prism Technologies. In addition, Greg served as a director and audit committee chairman of Celsion from 2005-2011, as a director with the Washington State WBBA, and has consulted with other biotech companies throughout his career. Greg began his career as a Certified Public Accountant with Arthur Andersen. He has a Master of Business Administration from Boston College and Bachelor of Science from Trinity University.
"I appreciate the opportunity to join the Board of Directors of Atossa Genetics at this important juncture," commented Weaver. "Atossa has the potential to make a significant contribution toward women's breast health and I look forward to the future success of the Company."
About Atossa Genetics, Inc.
Atossa Genetics, Inc. is focused on the commercialization of patented, diagnostic medical devices and, through its wholly-owned subsidiary, The National Reference Laboratory for Breast Health, Inc. (NRLBH), patented, laboratory developed tests. The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.
For additional information please visit www.atossagenetics.com.
Forward-looking statements in this Press Release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the outcome or timing of regulatory clearances needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, recalls of products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors, estimated future expenses and cash needs, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Source: Atossa Genetics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.